However, from the age of 3 (or 6) months, both paracetamol and ib

However, from the age of 3 (or 6) months, both paracetamol and MAPK Inhibitor Library ibuprofen are suitable (Table 4). Antipyretic efficacy data for ibuprofen and paracetamol are not relevant to the use of these agents in feverish children, considering the NICE guidance to focus on comforting the child, rather than on achieving normothermia. However, they do provide useful information. Antipyretic efficacy

may indicate relevant pharmacologic onset and duration of effect, especially where distress is due to the mismatch in environmental and body temperatures. However, distress is likely multi-factorial so antipyretic efficacy cannot currently be used as a direct surrogate for efficacy against distress in feverish children; further research is required.

The evidence indicates that ibuprofen may provide greater relief of symptoms in the distressed, feverish child compared with paracetamol [26, 27]. The longer duration of Selleckchem HDAC inhibitor action of ibuprofen means the number of doses can be kept to a minimum, and a single dose may be all that is required in certain circumstances (e.g., post-immunization pyrexia). In addition, the faster onset of action and greater symptomatic relief with ibuprofen means that the NICE recommendation to relieve distress can be achieved more rapidly, with the concomitant advantage of a faster return to ‘normal’ family life. Meta-analyses confirm that the safety and tolerability profiles of paracetamol and ibuprofen in pediatric fever are similar Progesterone [25, 33]. Both drugs are associated with specific rare adverse effects, which are difficult to detect and quantify in all but the largest clinical trials, and which may be relevant to specific patient selleck chemicals llc populations. For example, ibuprofen may be preferable in the setting of asthma (without known aspirin sensitivity) or where there is a risk of the parent or caregiver experiencing confusion overdosing (and potentially overdosing the child), whilst paracetamol may be preferable when children have chicken pox, are dehydrated, have pre-existing renal

disease or multi-organ failure, or are at increased risk of GI bleeding (Table 3). In reality, such children are likely to be under the care of a clinician, who is best placed to weigh up the risks and benefits of each drug for the individual patient. Paracetamol is generally conceived by the public (or HCPs) as being a ‘safer agent’ with fewer adverse effects. Possible reasons to explain this misconception could include the earlier potential exposure to paracetamol (after the child’s first immunization at 2 months of age), perhaps leading to a general misconception around its safety and tolerability. Therefore, with earlier familiarity, in the absence of advice to the contrary, many parents are likely to remain loyal to a drug they are used to. In addition, the fact that paracetamol is licensed for use in younger children may mean that parents perceive it to be a ‘safer’ medication.

Selective emergency LC for colon cancer performed by experienced

Selective emergency LC for colon cancer performed by experienced specialist colorectal surgeons is not inferior to open surgery with regard to short- and long-term outcomes. LC resulted in a shorter length of hospital see more stay. LC stands for laparoscopic colectomy; LHC for laparoscopic hand-assisted colectomy; OC for open colectomy; ICU for intensive care unit. Overall, the 7 studies evaluating laparoscopic colectomy in emergency or urgent setting concluded that this technique is a safe and feasible option associated with lower blood loss and shorter hospital stay. Laparoscopy may require longer operative time, but morbidity and mortality rates appeared comparable to open colectomy.

The conversion rate ranged from 0 to 17%. Previous studies on the role of a laparoscopic colectomy in treating patients with acute colitis from inflammatory bowel disease or iatrogenic perforation following colonoscopy were able to demonstrate the safety, feasibility and benefits of the laparoscopic

approach [23–25]. However, data on the specific case of laparoscopic colectomy for obstructed or hemorrhagic colon carcinoma are rare, and caution should be paid before drawing conclusions because the available studies KU-57788 mw investigated only small or heterogeneous samples of patients most of the times presenting with a high variety of surgical indications and diagnosis (5/7 studies included patients operated for both malignant and non-malignant pathologies). Notwithstanding, emergency laparoscopy seems a valuable option but all studies stressed the importance of the surgeon’s experience in elective colorectal laparoscopic procedures and the role of patient selection. It remains under debate which are the precise criteria to select the adequate candidates for minimally invasive colectomy in emergent or urgent settings. Conclusions Right colon cancer may present as an emergency, although this occurs

in a minority of patients. A minimally invasive approach can be used if the general Vorinostat purchase conditions of the patient are adequate and the vital prognosis is not affected by a longer procedure or a delayed operation. Robotic surgery still does not have a definite role in colorectal surgery, but its indication is growing constantly. Usually performed for specific sub-groups of elective patients, robotic surgery may also be successfully used in urgent settings with good postoperative and oncologic outcomes. Consent Written informed consent was obtained from the patient for publication of this Case Report and any accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal. Authors’ buy MLN2238 information EF: MD, Consultant in General Surgery. FB: MD, Consultant in Upper and Lower Gastrointestinal Surgery. CS: MD, Consultant in Hepato-biliary and liver transplantation.

J Allergy Clin Immunol 2001,108(4):516–520 PubMedCrossRef 61 Sto

J Allergy Clin Immunol 2001,108(4):516–520.PubMedCrossRef 61. Storrø O, Oien T, Langsrud O, Rudi K, Dotterud C, Johnsen R: Temporal variations in early gut microbial colonization are associated with allergen-specific

immunoglobulin E but not atopic eczema at 2 years of age. Clin Exp Allergy 2011,41(11):1545–1554.PubMedCrossRef 62. Andersson AF, Lindberg M, Jakobsson H, Bäckhed F, Nyren P, Engstrand L: Comparative analysis of human gut microbiota by barcoded pyrosequencing. PLoS One 2008,3(7):e2836.PubMedCrossRef 63. Xu J, Bjursell MK, Himrod J, Deng S, Carmichael LK, Chiang HC, Hooper LV, Gordon JI: A genomic view of the human-Bacteroides thetaiotaomicron symbiosis. Science 2003,299(5615):2074–2076.PubMedCrossRef 64. Koenig JE, Cediranib molecular weight Spor A, Scalfone

N, Fricker AD, Stombaugh J, Knight R, Angenent LT, Ley RE: Succession of microbial consortia in the developing infant gut microbiome. Proc Natl Acad Sci USA 2011,108(Suppl 1):4578–4585.PubMedCrossRef 65. Mazmanian SK, Liu CH, Tzianabos AO, Kasper DL: An immunomodulatory molecule of symbiotic bacteria directs maturation of the host immune system. Cell 2005,122(1):107–118.PubMedCrossRef 66. Penders J, Thijs C, van den Brandt PA, Kummeling I, Snijders B, Stelma F, Adams H, van Ree R, Stobberingh EE: Gut microbiota composition and development of atopic manifestations in infancy: the KOALA Birth Cohort Study. Gut 2007,56(5):661–667.PubMedCrossRef 67. Sato T, Matsumoto K, Okumura T, Yokoi W, Naito E, Yoshida Y, Nomoto K, Ito M, Sawada H: Isolation of lactate-utilizing butyrate-producing bacteria from human feces and

in vivo administration of Anaerostipes caccae strain L2 and galacto-oligosaccharides in a rat model. FEMS Microbiol Ecol 2008,66(3):528–536.PubMedCrossRef 68. Bibiloni R, Simon MA, Albright C, Sartor B, Tannock GW: Analysis of the large bowel microbiota of colitic mice using PCR/DGGE. Lett Appl Microbiol 2005,41(1):45–51.PubMedCrossRef Competing interests The authors declare that they have no competing interests. Authors’ contributions MK and ES designed the original intervention study and organized the sample collection. Infants were clinically examined by MK. LN, WMdV, RS and SS designed the current study. LN performed faecal Carbohydrate microbial DNA extraction, qPCR analyses and HITChip experiments. MR-S was involved in HITChip experiments. JN performed bioinformatic analyses. LN, RS and WMdV interpreted the results and wrote the paper. All authors read and approved the final manuscript.”
“Background Candida albicans is a ubiquitous commensal in healthy individuals; it is, however, a very important opportunistic pathogen for immunologically weak and immuno-compromised people [1]. Recurrent and/or BYL719 mw persistent infections by Candida species are frequent, particularly in oropharyngeal and vaginal candidiasis, although it has also been described in urinary tract infections [2].

(b) Mean rainfall (mm) in Dec, 2010/Oct, 2011- data obtained from

(b) Mean rainfall (mm) in Dec, 2010/Oct, 2011- data obtained from Bureau of Meteorology, Government of Australia In Central Queensland, spring and summer seasons (November, 2010 to March, 2011) are accompanied by heavy rainfall. Figure 8 (b)

shows the mean rainfall of each month from Dec, 2010 to Oct 2011. Figure 8 (a) showed the turbidity levels of the pond water varied over the range 8–76 NTU during the period Dec, 2010- Oct, 2011. Comparing the data from Figure 8 (a) and (b), it can be determined that the turbidity BIBW2992 price levels were lowest (8–16 NTU) during the summer period which is linked to heavy rainfall conditions, with a high mean rainfall of 180 mm in Jan, 2011. During winter minimal rainfall was observed with a low in August of 22 mm of around rain when the turbidity level was high, at 76 NTU. So it is logical to interpret from these observations that the summer season will provide

better microbial photocatalytic inactivation over the winter period due to a combination of high sunlight and lower turbidity. Discussion This study has showed that there was a relatively small effect of pH 7.0 and pH 9.0 on microbial inactivation. pH 5.0 showed a different result in Figure 2 with a lower initial counts. As, the acceptable range of a healthy aquaculture system is within the pH range of 6.5 to 9 [14], the findings from Figure 2 at pH levels of 7.0 and 9.0 demonstrates that there is no major Aprepitant pH effect against A. hydrophila inactivation over this pH range. Rincon and Pulgarin [18] suggested Idasanutlin datasheet that

modifications of water pH between 4 and 9 had no effect on photocatalytic batch culture solar disinfection of E. coli. However, the catalyst would be more negatively charged at high pH and the result is therefore not as might be predicted on the basis of charge alone, indicating that other factors must be involved. To clarify the reduced initial count at pH 5.0 in Figure 2, a longer-term storage experiments was performed over 9 h (Figure 3) to find out the survival BAY 63-2521 research buy capacity of A. hydrophila at pH levels of 5.0, 7.0 and 9.0. This illustrated that in darkness, pH 5.0 negatively affected the survival of A. hydrophila. Some previous aquaculture studies provided evidences that low pH levels are not suitable for growth and survival of fish species [6, 13, 42]. Therefore, the result at pH 5.0 is of less direct relevance to aquaculture systems, since this is not within the usual range of operations. Fresh water ponds, tanks and cages provided 60% of the total aquaculture production of the world in 2008 [43]. Similarly, coastal ponds and tanks also produce fish, molluscs, crustaceans etc. In warm regions, prawns and shrimps mainly dominate the world’s total aquaculture production, 58% of which comes from brackish water supply [44].

The commercial

Bt species are believed to be non-infectio

The commercial

Bt species are believed to be non-infectious and have only on rare occasions been associated with opportunistic infections in humans. Nevertheless, the close relationship ARN-509 datasheet between Bt and the human pathogen Bacillus cereus continues to be substantiated and gives rise to new questions [26–29]. The present study showed that instilled or even inhaled Bt spores may be present in the lung and extracted by BAL 70 days after administration. Our data are in line with other clearance studies, demonstrating CFU of Bt kurstaki in the liver, spleen and lungs 21 days after intratracheal (i.t.) instillation and similar patterns were seen with Bt aizawai and B. subtilis. Clearance patterns after i.v. injection with 107 CFU per animal is also reported for Bt kurstaki, Bt israelensis, B. subtilis and B. sphaericus. All strains were still recovered from inner organs at the termination of the study (day 57 for Bt israelensis CRT0066101 mouse and 128 for Bt kurstaki) [30, 31]. As Bt formulations are used for spray application, hazard identification and risk assessment should be based on airway effects. To our knowledge, the present study is the first to investigate airway irritation and airway inflammation induced

by inhalation of commercial Bt biopesticides. The i.t. instillation of biopesticide, showed that a single exposure gave rise to focal areas of lung tissue inflammation still detectable 70 days after exposure. A clear see more dose-response relationship was seen. Inflammation was also seen 70 days after repeated inhalation

of Bt biopesticide, although the effects after inhalation were less vigorous than after instillation. The sub-chronic inflammation was apparent as small patches of interstitial inflammation, a response that was not detectable in the corresponding Succinyl-CoA BAL fluid. The sub-chronic inflammation observed in the present study, was most likely due to the prolonged presence of Bt spores or other product residues in the lungs, triggering and maintaining the inflammatory response. This should be seen in the light that the formulated biopesticides contains only about 2% spores and 98% other ingredients according to manufacturer which makes long term inhalation studies using the final formulated biopesticide important. The list of other ingredients besides water is known to authorities (e.g. the EPA) and approved for other purposes e.g. a “”food- carbohydrate”" and preservatives [32]. Most of these other ingredients have probably not been subjected to long term inhalation studies in animals as this was not their intended use. Therefore alternative inoculums or controls, including spore free or heat-inactivated biopesticide or specific excipients/additives should also be studied for biological effect.

The total number of

The total number of apoptotic cells in 10 randomly selected fields was counted. The apoptotic index (AI) was calculated as the percentage of positive staining cells, namely AI = number of apoptotic cells × 100/total number of nucleated cells. Statistics Results were expressed as mean ± standard deviation (SD) and were analyzed with a one-way ANOVA and SPSS18.0 software package used to YH25448 manufacturer perform statistical analysis. A value of P < 0.05 was considered significant between the experimental Eltanexor solubility dmso groups compared with other groups. Results Expression of ATM in ATM AS-ODNs transfected Hep-2 cells To analyze the expression of ATM in mRNA and protein level in Hep-2 cells, real-time fluorescent quantitative PCR and western blot assay were

used respectively. It is evident that there were no significant differences among the groups treated with liposome alone, with Sen-ODNs and with Mis-ODNs after 72 hours treatment (P > 0.05; Figure 1). However when incubated with liposome formulations of ATM AS-ODNs, the relative ATM mRNA expression was only about 11.03 ± 2.51% to the untreated Hep-2 cells, which showed a significantly reduced expression of ATM

mRNA (P < 0.05;Figure 1). As shown in Figure 2, ATM protein expression was PD0332991 clinical trial also significantly reduced by ATM AS-ODNs compared with Sen-ODNs and Mis-ODNs after 72 hours treatment (Figure 2A). The relative ATM protein expression of Hep-2 cells treated with ATM AS-ODNs was only about 48.14 ± 5.53% to the untreated cells (P < 0.05; Figure 2B). But there was no significant difference among the group treated

with liposome alone, the group treated with Sen-ODNs, the group treated with Mis-ODNs and the group of control untreated Hep-2 cells (P > 0.05; Figure 2B). Figure 1 Real-time quantitative PCR analysis of ATM mRNA expression. Liposome formulations of ATM AS-ODNs decreased expression of ATM mRNA was notably lower than that of other groups. There are no significant differences among liposome-treated group (Lipo), Sen-ODNs (Sen-Lipo) treated group and Mis-ODNs (Mis-Lipo) treated group (P > 0.05). P < 0.05, AS-ODNs (AS-Lipo) treated group compared with other groups. Figure 2 A Effect of ATM AS-ODNs on the expression of ATM protein in vitro. (A) Liposome formulations of ATM AS-ODNs dramatically reduced the expression of ATM protein compared with other groups. (B) There are no significant Oxymatrine differences among liposome-treated group (Lipo), Sen-ODNs (Sen-Lipo) treated group and Mis-ODNs (Mis-Lipo) treated group (P > 0.05), while the group treated with ATM AS-ODNs notably different compared with other groups (**P <0.05). ATM AS-ODNs on clonogenic survival ability of Hep-2 cells after irradiation Cloning efficiency, P <0.05, was declined in cells transfected with ATM AS-ODNs compared with untreated cells or cells treated with control at the identical radioactive dose (Figure 3). After 4 Gy radiation, the survival fraction (SF4) revealed the cellular radio-induced apoptosis.

NABTT CNS Consortium The New Approaches to Brain Tumor Therapy

NABTT CNS Consortium. The New Approaches to Brain Tumor Therapy. Cancer Chemother Pharmacol 1998, 42: 118–126.CrossRefPubMed

19. Martinez W, Ingenito A, Blakeslee M, Captisol concentration Barkley GL, McCague K, D’Souza J: Efficacy, safety, and tolerability of oxcarbazepine TPCA-1 price monotherapy. Epilepsy Behav 2006, 9: 448–456.CrossRefPubMed 20. Baruzzi A, Albani F, Riva R: Oxcarbazepine: pharmacokinetic interactions and their clinical relevance. Epilepsia 1994, 35 (suppl 3) : 14–19.CrossRef 21. Larkin JG, McKee PJ, Forrest G, Beastall GH, Park BK, Lowrie JI, Lloyd P, Brodie MJ: Lack of enzyme induction with oxcarbazepine (600 mg daily) in healthy subjects. Br J Clin Pharmacol 1991, 31: 65–71.PubMed 22. Cancer Therapy Evaluation Program, Common Terminology Criteria for Adverse Events v3.0, DCTD, NCI, NIH, DHHS, December 12, 2003 [http://​ctep.​cancer.​gov/​protocolDevelopm​ent/​electronic_​applications/​docs/​ctcae_​index.​pdf#search=​""ctcae""] find more 23. Taillibert S, Laigle-Donadey F, Sanson

M: Palliative care in patients with primary brain tumors. Curr Opin Oncol 2004, 16: 587–592.CrossRefPubMed 24. Hildebrand J: Management of epileptic seizures. Curr Opin Oncol 2004, 16: 314–317.CrossRefPubMed 25. Zaccara G, Messori A, Cincotta M, Burchini G: Comparison of the efficacy and tolerability of new antiepileptic drugs: what can we learn from long-term studies? Acta Neurol Scand 2006, 114: 157–168.CrossRefPubMed 26. Alvestad S, Lydersen S, Brodtkorb E: Rash from antiepileptic drugs: influence by gender, age, and learning disability. Epilepsia 2007, 48: 1360–1365.CrossRefPubMed 27. Meyers CA: Neuropsychological deficits in brain tumor patients: Effect of location, chronicity, and treatment. Cancer Bull 1986, 38: 30–32. 28. Meyers CA, Boake C: Neurobehavioral disorders in brain tumor patients: Rehabilitation strategies. Cancer Bull 1993, 45: 362–364. 29. Brunbech L, Sabers A: Effect of Tau-protein kinase antiepileptic drugs on cognitive function in individuals with epilepsy: a comparative

review of newer versus older agents. Drugs 2002, 62: 593–604.CrossRefPubMed 30. Villikka K, Kivistö KT, Mäenpää H, Joensuu H, Neuvonen PJ: Cytochrome P450-inducing antiepileptics increase the clearance of vincristine in patients with brain tumors. Clin Pharmacol Ther 1999, 66: 589–593.PubMed 31. Dogan EA, Usta BE, Bilgen R, Senol Y, Aktekin B: Efficacy, tolerability, and side effects of oxcarbazepine monotherapy: A prospective study in adult and elderly patients with newly diagnosed partial epilepsy. Epilepsy Behav 2008, 13: 156–161.CrossRefPubMed 32. Brada M, Viviers L, Abson C, Hines F, Britton J, Ashley S, Sardell S, Traish D, Gonsalves A, Wilkins P, Westbury C: Phase II of primary temozolomide chemotherapy in patients with WHO grade II gliomas. Ann Oncol 2003, 14: 1715–1721.

Data extraction Hazard Ratios (HR) for PFS

and OS and the

Data extraction Hazard Ratios (HR) for PFS

and OS and the number of events for secondary end-points were extracted; the last trial’s available update was considered as the original source. All data were reviewed and separately computed by four investigators (F.Cu., E.B., I.S., and D.G.). Data synthesis HRs were extracted from each single trial for primary end-points Fludarabine [19, 20], and the log of relative risk ratio (RR) was estimated for secondary endpoints [21]; 95% Confidence Intervals (CI) were derived [22]. A random-effect model according to DerSimonian-Laird method was preferred to the fixed, given the known clinical heterogeneity of trials; a Q-statistic heterogeneity test was used. Absolute benefits for LY3039478 nmr each outcome were calculated (i.e. absolute benefit = exp HR or RR × log[control survival] – control survival [23]; modified by Parmar and Machin [24]). The number of patients needed to treat (or to harm one in

case of toxicity) for one single beneficial patient was determined (NNT or NNH: 1/[(Absolute Benefit)/100]) [25]. Results were depicted in all figures as conventional meta-analysis forest plots. In order to find possible correlations between outcome effect and negative prognostic factors (selected among trials’ reported factors: > 3 sites, no adjuvant CT, visceral site, hormonal receptors negative (RN), prior taxanes, T or anthracyclines, A) a Thiazovivin cell line meta-regression approach was adopted (i.e. regression of the selected predictor on the Log HR/RR of the corresponding outcome). Calculations were accomplished using the Comprehensive Meta-Analysis Software, version v. 2.0 (CMA, Biostat, Englewood, NJ, USA). Results Selected

trials Five trials (3,841 patients) were identified (Figure 1) [13, 14, 16, 26, 27], all included in the meta-analysis, and evaluable for PFS (primary outcome). The patients’ sample for each trial ranged from 462 to 736 patients Reverse transcriptase (Table 1). One trial was conducted with a double comparison [16]. Trials characteristics are listed in Table 1; 2 RCTs evaluated the addition of Bevacizumab as second line treatment [26, 27], and one of these included patients who received 2 or more regimens of chemotherapy for metastatic disease [27]. One trial (462 patients) did not report survival data [27], so 4 RCTs were evaluable for OS (3,379 patients). With regard to secondary outcomes, all RCTs were evaluable for ORR, HTN, Bleeding, Proteinuria and Thrombosis; 4 RCTs (3,379 patients) were evaluable for Neurotoxicity, Febrile Neutropenia, Gastro-intestinal perforation [13, 14, 16, 26].

QD participated in data acquisition KLG contributed to the mater

QD participated in data acquisition. KLG Veliparib ic50 contributed to the materials. All authors participated in drafting the manuscript, and read and approved the final manuscript.”
“Background Most bacteria have a regulatory system, known as quorum sensing (QS), to modulate gene expression as a function of their cell density (for reviews see [1, 2]). It usually works via

the production of a signaling molecule that reaches a threshold concentration at high cell density allowing its detection by the bacterial population and resulting in the modulation of target gene expression. In gram negative, N-acyl homoserine lactone signaling molecules (AHLs) are thus far the most common signal molecules produced. A typical AHL QS system involves two major components: an AHL synthase gene (belonging to the LuxI protein family) and a modular transcriptional response-regulator (belonging to the LuxR protein family) which detects

and responds to the AHL concentration selleckchem [3]. AHL QS thus far is exclusively found in proteobacteria; 68 of 265 sequenced proteobacterial genomes possess at least one luxI/R family pair [4]. Interestingly, 90 genomes contained at CX 5461 least one luxR gene having the modular characteristics of the QS-family of regulators; however it was not associated with a cognate luxI-family gene. Of these, 45 genomes harbor at least one complete AHL QS system in addition to one or more luxR gene/s. These unpaired LuxR family proteins were firstly designated orphans [5] and recently they have been proposed to be renamed as LuxR ‘solos’ [6]; a few of these LuxR solos are beginning to be studied. ExpR of Sinorhizobium meliloti, BisR of Rhizobium leguminosarum bv. viciae and QscR of Pseudomonas aeruginosa, are LuxR solo proteins in AHL producing bacteria which have been well characterized and shown to be integrated with

the resident complete AHL QS regulatory networks [7–10]. Only two solo LuxR homologs in non-AHL producing bacteria have thus far been investigated in some detail. One is called SdiA which is present in the Salmonella enterica and Escherichia coli and shown to be able PRKD3 to bind and detect AHLs produced by other bacteria. The other one is from plant pathogenic Xanthomonas spp. and in two Xanthomonas species it is involved in regulating virulence factors upon binding an unknown plant produced low molecular weight compound which is not an AHL [11–13]. This indicates that certain quorum sensing related LuxR family proteins are able to be involved in inter-kingdom signaling by detecting non-AHL compounds produced by eukaryotes. Pseudomonas putida strains are mainly studied either for their ability to establish beneficial association with plants or due to their versatile catabolic potential. Previous studies have indicated that the majority of soil-borne or plant-associated P. putida strains do not produce AHLs; apparently only about one third of strains belonging to these species have a complete AHL QS system [14, 15].

J Phys: Conf Ser 2008, 100:052095 CrossRef 39 Hashida M, Shimizu

J Phys: Conf Ser 2008, 100:052095.GDC-0068 supplier CrossRef 39. Hashida M, Shimizu S, Sakabe S: Carbon-nanotube cathode modified by femtosecond laser ablation. J Phys: Conf Ser 2007, 59:487.CrossRef 40. Guo SX, Ben-Yakar A: Femtosecond laser nanoablation of glass in the near-field of single wall carbon nanotube bundles. J Phys D Appl Phys 2008, 41:185306.CrossRef 41. Lednev VN, Pershin SM, Obraztsova ED, Kudryashov SI, Bunkin AF: Single-shot and single-spot measurement of laser ablation threshold for carbon nanotubes. J Phys D Appl Phys 2013, 46:052002.CrossRef 42. Reitze D, Ahn H, Downer M: Optical properties of

liquid carbon measured by femtosecond spectroscopy. Phys Rev B 1992, 45:2677.CrossRef 43. Roberts A, Cormode D, Reynolds C, Newhouse-Illige T, Le Roy

BJ, Sandhu AS: Response of graphene to femtosecond high-intensity laser irradiation. Appl Phys Lett 2011, 99:051912–051913.CrossRef Evofosfamide chemical structure 44. Gamaly E, Luther-Davies B, Kolev V, Madsen N, Duering M, Rode A: Ablation of metals with picosecond laser pulses: evidence of long-lived non-equilibrium surface states. Laser Part Beams 2005, 23:167–176.CrossRef 45. Hirayama Y, Atanasov P, Obara M, Nedialkov N, Imamova S: Femtosecond laser check details ablation of crystalline iron: experimental investigation and molecular dynamics simulation. Jpn J Appl Phys 2006, 45:792.CrossRef 46. Gamaly E, Rode A, Luther-Davies B, Tikhonchuk V: Ablation of solids by femtosecond lasers: ablation mechanism and ablation thresholds for metals and dielectrics. Phys Plasmas 2002, 9:949.CrossRef 47. Jeschke HO, Garcia ME, Bennemann K: Theory for the ultrafast ablation of graphite films. Phys Rev Lett 2001, 87:15003.CrossRef 48. Jeschke HO, Garcia ME: Theoretical description of the ultrafast ablation of diamond and graphite: dependence of thresholds on pulse duration. Appl Surf Sci 2002, 197:107–113.CrossRef 49. Eliezer S, Eliaz N, Grossman E, Fisher D, Gouzman I, Henis Z, Pecker S, Horovitz Y,

Fraenkel M, Maman S: Nanoparticles and nanotubes induced Metformin supplier by femtosecond lasers. Laser Part Beams 2005, 23:15–19.CrossRef Competing interests The authors declare that they have no competing interests. Authors’ contributions VL coordinated the study, analyzed the data, and contributed to the manuscript preparation. AP synthesized the CNT arrays, performed structural analyses of the samples, analyzed the experimental results, and contributed to the manuscript preparation. SB carried out the femtosecond laser irradiation of the CNT arrays and analyzed the data. SF performed EDX study of the irradiated CNTs. BS and BKT analyzed the data and contributed to the manuscript preparation. YS and AB carried out TEM and analyzed the data. All authors read and approved the final manuscript.